Vaccinex, Inc.

Equities

VCNX

US9186403013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 28/06/2024 am IST			5-day change	1st Jan Change
6.179 ^USD	+2.98%		-2.23%	-33.61%

06/06	Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer?s Disease	CI
16/05	Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000	MT

Vaccinex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 16, 2024 at 02:55 am IST

Vaccinex, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 0.104 million compared to USD 0.55 million a year ago. Net loss was USD 3.9 million compared to USD 4.96 million a year ago.

Basic loss per share from continuing operations was USD 2.94 compared to USD 20.89 a year ago. Diluted loss per share from continuing operations was USD 2.94 compared to USD 20.89 a year ago.

Latest news about Vaccinex, Inc.

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer?s Disease	06/06	CI
Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000	16/05	MT
Vaccinex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Vaccinex, Inc. announced that it has received $1.75 million in funding	12/04	CI
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding	29/03	CI
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	28/03	CI
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	27/03	CI
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding	27/03	CI
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024	05/03	CI
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	05/03	CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	22/02	MT
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	21/02	MT
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	21/02	CI
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding	07/02	CI
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting	31/23/31	CI
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases	26/23/26	CI
Top Premarket Gainers	06/23/06	MT
Vaccinex Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing	06/23/06	MT
Vaccinex Insider Bought Shares Worth $509,515, According to a Recent SEC Filing	06/23/06	MT
Top Midday Decliners	29/23/29	MT
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	29/23/29	MT
Top Premarket Decliners	29/23/29	MT
Vaccinex Prices Offering of Shares, Warrants for Gross Proceeds of About $9.6 Million	29/23/29	MT

Chart Vaccinex, Inc.

Duration

Period

More charts

Company Profile

Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâs disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VACCINEX, INC.	-33.61%	9.79M
VERTEX PHARMACEUTICALS INCORPORATED	+16.13%	122B
REGENERON PHARMACEUTICALS, INC.	+19.65%	113B
ARGENX SE	+21.22%	26.49B
BIONTECH SE	-23.84%	19.4B
GENMAB A/S	-17.47%	16.24B
WUXI APPTEC CO., LTD.	-45.95%	15.15B
BEIGENE, LTD.	-19.28%	15.4B
SAREPTA THERAPEUTICS, INC.	+63.81%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+1.94%	13.52B

Bio Therapeutic Drugs